B.O.S.S. Retirement Advisors LLC Has $304,000 Stock Position in Pfizer Inc. (NYSE:PFE)

B.O.S.S. Retirement Advisors LLC lowered its holdings in shares of Pfizer Inc. (NYSE:PFE) by 86.5% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 11,468 shares of the biopharmaceutical company’s stock after selling 73,584 shares during the period. B.O.S.S. Retirement Advisors LLC’s holdings in Pfizer were worth $304,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Fred Alger Management LLC increased its holdings in shares of Pfizer by 6.6% in the second quarter. Fred Alger Management LLC now owns 95,592 shares of the biopharmaceutical company’s stock valued at $2,675,000 after purchasing an additional 5,932 shares during the last quarter. Caxton Associates LP acquired a new stake in Pfizer in the 2nd quarter worth about $738,000. AQR Capital Management LLC boosted its holdings in Pfizer by 1.6% in the 2nd quarter. AQR Capital Management LLC now owns 612,429 shares of the biopharmaceutical company’s stock valued at $17,068,000 after purchasing an additional 9,435 shares during the period. Sender Co & Partners Inc. acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $499,000. Finally, Smith Thornton Advisors LLC bought a new position in shares of Pfizer during the second quarter worth approximately $311,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $26.10 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm’s fifty day simple moving average is $26.11 and its two-hundred day simple moving average is $27.94. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a market capitalization of $147.89 billion, a P/E ratio of 35.27, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.17) EPS. As a group, analysts predict that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.59%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is presently 227.03%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Guggenheim cut their price target on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Wolfe Research initiated coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Citigroup assumed coverage on Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. This represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.